{"title":"氨苯丙啶(3,4二氨基吡啶和3,4磷酸二氨基吡啶):兰伯特-伊顿肌无力综合征的首选药物","authors":"Shin J Oh","doi":"10.35248/2329-9096.21.S4.005","DOIUrl":null,"url":null,"abstract":"Amifampridines have been known to be effective as symptomatic treatment of Lambert-Eaton myasthenic syndrome since 1983. Food Drug Administration (FDA) approved amifampridines, the most studied safe and effective drugs in the neuromuscular diseases, are available for the general use for symptomatic treatment of LEMS, 60 years after the first description of LEMS and 40 years after the first trial of 3,4-DAP in LEMS.","PeriodicalId":14201,"journal":{"name":"International Journal of Physical Medicine and Rehabilitation","volume":"45 1","pages":"1-3"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Amifampridines (3,4 Diaminopyridine and 3,4 Diaminopyridine Phosphate): Drugs of Choice for Lambert-Eaton Myasthenic Syndrome\",\"authors\":\"Shin J Oh\",\"doi\":\"10.35248/2329-9096.21.S4.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Amifampridines have been known to be effective as symptomatic treatment of Lambert-Eaton myasthenic syndrome since 1983. Food Drug Administration (FDA) approved amifampridines, the most studied safe and effective drugs in the neuromuscular diseases, are available for the general use for symptomatic treatment of LEMS, 60 years after the first description of LEMS and 40 years after the first trial of 3,4-DAP in LEMS.\",\"PeriodicalId\":14201,\"journal\":{\"name\":\"International Journal of Physical Medicine and Rehabilitation\",\"volume\":\"45 1\",\"pages\":\"1-3\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Physical Medicine and Rehabilitation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35248/2329-9096.21.S4.005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Physical Medicine and Rehabilitation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/2329-9096.21.S4.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Amifampridines (3,4 Diaminopyridine and 3,4 Diaminopyridine Phosphate): Drugs of Choice for Lambert-Eaton Myasthenic Syndrome
Amifampridines have been known to be effective as symptomatic treatment of Lambert-Eaton myasthenic syndrome since 1983. Food Drug Administration (FDA) approved amifampridines, the most studied safe and effective drugs in the neuromuscular diseases, are available for the general use for symptomatic treatment of LEMS, 60 years after the first description of LEMS and 40 years after the first trial of 3,4-DAP in LEMS.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
